SYS-CON MEDIA Authors: Ian Khan, Liz McMillan, AppDynamics Blog, Harry Trott, Blue Box Blog

News Feed Item

Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation



 

 

 

 

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation


Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation

Summary

GBI Research has released its pharmaceuticals report, "Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation". The Alzheimer's Disease (AD) market is characterized by a lack of products with strong disease-modifying properties and a number of high-profile product failures in late stages of development over recent years. In addition, recent or impending patent expiries for all of the four currently marketed products and a late-stage pipeline with limited-to-moderate prospects are expected to impede growth over the next few years. In the medium-term future, the market is expected to be characterized by substantial generic competition and overall decline. However, the current development pipeline shows signs of meaningful innovation, although the vast majority of these products are currently in the early stages of development. Despite one of the highest drug attrition rates across the industry, a number of innovative and potentially disease-modifying therapeutics are likely to enter the market and translate recent insights into the etiology of AD combined with an earlier therapeutic intervention into better products, which will begin to transform the AD market towards the end of the decade.


Scope

- A brief introduction to AD etiology, pathogenesis, diagnosis, and treatment regimes
- Profiling of the marketed products in the AD market, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses
- Comprehensive review of the pipeline for AD therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule type, and molecular target.
- Additional in-depth analysis of pipeline drug clinical trials, analyzed by phase, molecule type, trial size, trial duration and program failure rate, for each molecule type and mechanism of action
- Multi-scenario forecast data for the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Japan, Germany, the UK, France, Italy and Spain
- Discussion of the drivers of and barriers to market growth
- Analysis of the licensing and co-development deals landscape

Reasons to buy

- Understand the different levels of AD therapies, from early-stage or mild AD to severe AD
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
- Observe trends in terms of clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for AD therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the AD therapeutics market
Table of Contents

1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Symptoms 8
2.2 Etiology 9
2.3 Pathophysiology 10
2.3.1 Amyloidosis 10
2.3.2 Tau Hyperphosphorylation 10
2.4 Comorbidities/Complications 11
2.5 Diagnosis 11
2.5.1 Physical Examination 12
2.5.2 Mini Mental State Exam 12
2.5.3 Alzheimer's Disease Assessment Scale-cognitive 14
2.5.4 Alzheimer's Disease Co-operative Study – Activities of Daily Living Inventory 15
2.5.5 Other Diagnostic Tests 15
2.5.6 Blood Tests 15
2.5.7 Imaging Tests 15
2.5.8 Lumbar Puncture 15
2.5.9 Disease Biomarkers 16
2.5.10 Biomarker Market 17
2.6 Prognosis 18
2.7 Treatment Options 18
2.7.1 Treatment Algorithm 19
2.7.2 Non-Pharmacological Treatments 19
3 Marketed Products 20
3.1 Namenda/Axura/Memary (memantine), Merz Pharma/Lundbeck/Forest Laboratories/Daiichi Sankyo 20
3.2 Aricept (donepezil), Eisai Inc. 21
3.3 Exelon (rivastigmine), Novartis AG 22
3.4 Razadyne (galantamine), Janssen Pharmaceuticals 22
3.5 Cognex (tacrine), Shiniogi Inc. 23
3.6 Unmet Need 24
4 Pipeline for Alzheimer's Disease Therapeutics 25
4.1 Overall Pipeline 25
4.2 Mechanisms of Action within the AD Pipeline 27
4.3 Clinical Trials 29
4.3.1 Clinical Trial Failure Rate 29
4.3.2 Clinical Trial Size 33
4.3.3 Clinical Trial Duration 35
4.4 Notable Pipeline Drugs 38
4.4.1 Solanezumab – Eli Lilly and Company 38
4.4.2 LMTX (Methylene Blue) – TauRX Therapeutics Ltd. 39
4.4.3 RG-1540 (gantenerumab) – Roche 39
4.4.4 AD-02 – AFFiRiS AG 40
4.4.5 MK-8931 – Merck & Co. 41
4.4.6 CAD-106 – Novartis AG 41
4.4.7 LuAE58054 – Lundbeck 42
4.4.8 Crenezumab (RG7412) – Genentech 42
4.5 Conclusion 42
5 Market Forecast to 2019 44
5.1 Geographical Markets 44
5.1.1 Key Developed Markets 44
5.1.2 US 47
5.1.3 Leading Five EU Countries (EU5) 49
5.1.4 Japan 53
5.2 Drivers and Barriers 55
5.2.1 Drivers 55
5.2.2 Barriers 56
6 Deals and Strategic Consolidations 58
6.1 Key Licensing Deals 58
6.1.1 Forest Laboratories Inc. Enters into Agreement with Adamas Pharmaceuticals Inc. 60
6.1.2 AC Immune SA Enters into an Agreement with Genentech Inc. 60
6.1.3 Cephalon Inc. Enters into Agreement with Mesoblast Limited 60
6.1.4 Acadia Pharmaceuticals Inc. Enters into Agreement with Biovail Laboratories International SRL 60
6.1.5 Astellas Pharma Inc. enters into Agreement with CoMentis Inc. 61
6.2 Key Co-development Deals 61
6.2.1 Evotec AG Enters into Agreement with F. Hoffman-La Roche Ltd. 63
6.2.2 Alectos Therapeutics Inc. Enters into Agreement with Merck & Co. Inc. 63
6.2.3 Targacept Inc. Expands Agreement with AstraZeneca PLC. 63
6.2.4 GlaxoSmithKline Enters into an Agreement with Epix Pharmaceuticals 64
7 Appendix 65
7.1 All Pipeline Drugs by Phase – Tables 65
7.2 Market forecast to 2019 - Tables 81
7.3 References 84
7.4 Abbreviations 87
7.5 Methodology 89
7.6 Secondary Research 89
7.7 Therapeutic Landscape 90
7.8 Contact Us 90
7.9 Disclaimer 90



List of Tables


Table 1: Alzheimer's Disease, Global, All Pipeline Products (Discovery) 65
Table 2: Alzheimer's Disease, Global, All Pipeline Products (Preclinical) 68
Table 3: Alzheimer's Disease, Global, All Pipeline Products (Phase I) 76
Table 4: Alzheimer's Disease, Global, All Pipeline Products (Phase II) 79
Table 5: Alzheimer's Disease, Global, All Pipeline Products (Phase III) 81
Table 6: Alzheimer's Disease, Global, Market Forecast, 2012–2019 81
Table 7: Alzheimer's Disease, US, Market Forecast, 2012–2019 81
Table 8: Alzheimer's Disease, UK, Market Forecast, 2012–2019 82
Table 9: Alzheimer's Disease, France, Market Forecast, 2012–2019 82
Table 10: Alzheimer's Disease, Germany, Market Forecast, 2012–2019 82
Table 11: Alzheimer's Disease, Italy, Market Forecast, 2012–2019 83
Table 12: Alzheimer's Disease, Spain, Market Forecast, 2012–2019 83
Table 13: Alzheimer's Disease, Japan, Market Forecast, 2012–2019 83



List of Figures



Figure 1: Mini-Mental State Exam 13
Figure 2: Alzheimer's Disease Assessment Scale Cognitive Subscale 14
Figure 3: Alzheimer's Disease, Overall Pipeline 26
Figure 4: Alzheimer's Disease, Mechanisms of Action in the Pipeline, 2006–2013 29
Figure 5: Alzheimer's Disease, Failure Rates of Clinical Trials, 2006–2013 30
Figure 6: Alzheimer's Disease, Failure Rates by Mechanism of Action, 2006–2013 31
Figure 7: Alzheimer's Disease, Reasons for Clinical Trial Failure, 2006–2013 32
Figure 8: Alzheimer's Disease, Clinical Trial Size by Phase, 2006–2013 33
Figure 9: Alzheimer's Disease, Clinical Trial Size by Molecule Type, 2006–2013 34
Figure 10: Alzheimer's Disease, Clinical Trial Duration by Phase, 2006–2013 35
Figure 11: Alzheimer's Disease, Clinical Trial Duration by Molecule Type, 2006–2013 36
Figure 12: Alzheimer's Disease, Global, 2012–2019 46
Figure 13: Alzheimer's Disease, US, 2012–2019 48
Figure 14: Alzheimer's Disease, EU5, Patient Number ('000) 2012–2019 50
Figure 15: Alzheimer's Disease, EU5, Annual Cost of Treatment ($), 2012–2019 51
Figure 16: Alzheimer's Disease, EU5, Market Size ($m), 2012–2019 52
Figure 17: Alzheimer's Disease, Japan, 2012–2019 54
Figure 18: Alzheimer's Disease, Global, Licensing Deals by Region and Year, 2012–2019 58
Figure 19: Alzheimer's Disease, Global, Licensing Deals by Phase and Molecule Type, 2012–2019 59
Figure 20: Alzheimer's Disease, Global, Co-development Deals by Region and Year, 2012–2019 61
Figure 21: Alzheimer's Disease, Global, Co-development Deals by Phase and Molecule Type, 2006–2013 62


Read the full report:
Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation
http://www.reportbuyer.com/pharma_healthcare/treatments/alzheimers_disea...

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Open Data Centers (ODC), a carrier-neutral colocation provider, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place June 9-11, 2015, at the Javits Center in New York City, NY. Open Data Centers is a carrier-neutral data center operator in New Jersey and New York City offering alternative connectivity options for carriers, service providers and enterprise customers.
SYS-CON Events announced today that Dyn, the worldwide leader in Internet Performance, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Dyn is a cloud-based Internet Performance company. Dyn helps companies monitor, control, and optimize online infrastructure for an exceptional end-user experience. Through a world-class network and unrivaled, objective intelligence into Internet conditions, Dyn ensures...
This builds on Puppet Labs' first class Windows support, including native .MSI packages for x32 and x64 operating systems, modules to extend common Windows server management tools, including Powershell, and integrations with Microsoft Azure and Visual Studio. By automating common Windows administration tasks, Puppet Labs is enabling users to adopt DevOps practices, thereby reducing the time needed to deploy applications from weeks to hours.
SYS-CON Events announced today that Vicom Computer Services, Inc., a provider of technology and service solutions, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. They are located at booth #427. Vicom Computer Services, Inc. is a progressive leader in the technology industry for over 30 years. Headquartered in the NY Metropolitan area. Vicom provides products and services based on today’s requirements...
BlueBox bridge the chasm between development and infrastructure. Hosting providers are taking standardization and automation too far. For many app developers it does nothing but spawn mayhem and more work. They have to figure out how their creations live on a pre-fab infrastructure solution full of constraints. Operations-as-a-Service is what BlueBox does. BlueBox utilizes development tools such as OpenStack, EMC Razor, Opscode’s Chef and BlueBox's proprietary tools give the power to do the unor...
What’s inside the cloud? Hard work. Cloud operators know the world inside the datacenter is gritty. Vendor marketing speak and cloudwashing quickly melt in the heat of SLAs, uptime guarantees, and users who want it now. In his session at DevOps Summit, Hernan Alvarez, Chief Product Officer at Blue Box Group, will deliver an unvarnished look inside the world of cloud operators, from the perspective of someone who lives it. Attendees get a front-row look into the toolkits and processes that enabl...
Application metrics, logs, and business KPIs are a goldmine. It’s easy to get started with the ELK stack (Elasticsearch, Logstash and Kibana) – you can see lots of people coming up with impressive dashboards, in less than a day, with no previous experience. Going from proof-of-concept to production tends to be a bit more difficult, unfortunately, and it tends to gobble up our attention, time, and money. In his session at DevOps Summit, Otis Gospodnetić, co-author of Lucene in Action and founder...
We are all here because we are sold on the transformative promise of The Cloud. But what good is all of this ephemeral, on-demand infrastructure if your usage doesn't actually improve the agility and speed of your business? How must Operations adapt in order to avoid stifling your Cloud initiative? In his session at DevOps Summit, Damon Edwards, co-founder and managing partner of the DTO Solutions, will highlight the successful organizational, process, and tooling patterns of high-performing c...
Physical, virtual, containers. Private cloud, public cloud, hybrid cloud. IaaS, PaaS, SaaS. Windows, Linux, Mac. These are just some of the choices faced when architecting a datacenter of today. And the choice is not one or the other; instead, it is often a combination of many of these. HashiCorp builds software to ease these decisions by presenting solutions that bridge the gaps. HashiCorp's tools manage both physical machines and virtual machines, Windows, and Linux, SaaS and IaaS, etc. The co...
CloudBees, Inc., has announced a $23.5 million financing round, led by longtime CloudBees investor Lightspeed Venture Partners. Existing investors Matrix Partners, Verizon Ventures and Blue Cloud Ventures also participated in the round. The latest funding announcement follows earlier rounds of $4 million, $10.5 million and $10.8 million, bringing the total investment in CloudBees to just under $50 million since the company’s inception in 2010. Previous venture investment rounds were led by Ma...
SYS-CON Events announced today that Blue Box has been named “Bronze Sponsor” of SYS-CON's DevOps Summit New York, which will take place June 9-11, 2015, at the Javits Center in New York City, NY. Blue Box delivers Private Cloud as a Service (PCaaS) to a worldwide customer base. Built on a technology platform leveraging decades of operational expertise in cloud and distributed systems, Blue Box Cloud is a managed private cloud product available in both hosted and on-prem versions. Each Blue Box ...
DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete...
“The year of the cloud – we have no idea when it's really happening but we think it's happening now. For those technology providers like Zentera that are helping enterprises move to the cloud - it's been fun to watch," noted Mike Loftus, VP Product Management and Marketing at Zentera Systems, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
“We help people build clusters, in the classical sense of the cluster. We help people put a full stack on top of every single one of those machines. We do the full bare metal install," explained Greg Bruno, Vice President of Engineering and co-founder of StackIQ, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
“We are a managed services company. We have taken the key aspects of the cloud and the purposed data center and merged the two together and launched the Purposed Cloud about 18–24 months ago," explained Chetan Patwardhan, CEO of Stratogent, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.